You are here: Industry Insights > Ablynx

News List

Sanofi and Ablynx announce the successful results of the initial tender offer period worldpharmanews
May 23, 2018
Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx (Euronext Brussels and Nasdaq: ABLX) today announced the results of the initial tender offer period of Sanofi's previously announced tender offers to acquire all of the outstanding shares
Ablynx's vobarilizumab trial fails and sees two patient deaths in systemic lupus erythematosus pharmafile
March 27, 2018
Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint in a Phase 2 trial, presenting implications for Sanofi who will acquire the drug following its agreement to buy the firm for
Ablynx enters €3.9bn acquisition deal with Sanofi pharmaceutical-technology
January 31, 2018
Belgium-based Ablynx has signed a definitive agreement, under which all of its outstanding shares will be purchased by French firm Sanofi at €45 per share, amounting to a total of about €3.9bn.
Sanofi agreed to buy Ablynx for $4.8 B biospectrumasia
January 30, 2018
The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules
No Deal for Novo as Sanofi Swoops in With $4.85B Win for Ablynx biospace
January 30, 2018
Only a week after Sanofi ponied up $11.6 billion to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8 billion.
Rejected Again: Ablynx Turns Down Novo Nordisk's Sweetened $3.1B Bid biospace
January 09, 2018
Novo Nordisk A/S has twice made a bid to acquire Ablynx NV., and twice been rejected. The first bid was on Dec. 7, 2017, for about $31.57 per share in cash.
Ablynx and Sanofi collaborate for nanobody-based inflammatory disease treatments pharmaceutical-technology
July 24, 2017
Belgian biopharmaceutical company Ablynx has entered a research collaboration and global exclusive licensing agreement with French firm Sanofi to develop and commercialise nanobody-based therapeutics for the treatment of several immune-mediated inflammato
Sanofi, Ablynx sign $2.7bn research, licensing pact pharmatimes
July 24, 2017
Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
Ablynx, Sanofi Enter Into A Collaboration to Develop Nanobody Candidates americanpharmaceuticalreview
July 21, 2017
Ablynx has entered into a research collaboration and global exclusive licensing agreement with Sanofi initially focused on developing and commercializing Nanobody-based therapeutics,,,
Ablynx Initiates IND-enabling Tox Study in Merck Alliance contractpharma
June 28, 2017
Earns €2.5 million milestone payment

Previous page 1 2 Next page